Ijikwa sistemu mgbochi ọrịa megide osteosarcoma

N'ime afọ 30 gara aga enwere obere mgbanwe na ọgwụgwọ osteosarcoma (OS). Anyị raara onwe anyị nye ịgbanwe nke a. Site na Myrovlytis Trust, anyị na-akwado nyocha n'ime OS, na-elekwasị anya na ịchọta ọgwụgwọ ọhụrụ. Obi dị anyị ụtọ ịkpọsa na anyị enyela Dr Wolfgang Paster ego na Children'smụaka cancerỌrịa ebe mkpụrụ ndụ na-ekewa ma na-eto na-enweghị nchịkwa ma nwee ike gbasaa n'akụkụ ndị ọzọ nke ahụ. Ụlọ ọrụ nyocha, Vienna, Austria.

Cancer immunotherapy, where the patient’s own immune system is boosted to fight the cancer, has transformed the outlook for many cancers. However, for OS this has proven to be challenging. OS tumours are very good at hiding from the body’s own immune system. One of the key players in the immune system are T cells. These cells can recognise and kill target cells, including cancer cells. If we can identify targets of these T cells that are only found in OS cells, we may be able to develop new treatments and overcome some of the previous barriers to immunotherapy.

In this 1 year project, Wolfgang’s team will use cutting edge techniques to identify proteins that are only found in OS tumour samples. They will then test whether these proteins can be recognised by T cells in the laboratory. In the future, they hope that they will be able to use these target proteins as the basis for new therapies such as ogwu ogwu ogwu.

Lelee obere vidiyo a dị n'okpuru site na Wolfgang na-akọwa ọrụ ya ma ọ bụ gụọ nchịkọta ọrụ. A transcript nke vidiyo dị kwa.

Anyị ga-aga n'ihu na-enye ego nyocha n'ime OS ma kwalite nyocha n'ihu. Anyị ewepụtala usoro ego anyị maka 2023. Chọpụta ihe gbasara ihe anyị na-akwado na otu esi etinye akwụkwọ. Anyị na-anabatakwa ajụjụ ajuju site na email.